Bismuth subcitrate, metronidazole, and tetracycline and Toremifene interaction
Bismuth subcitrate, metronidazole, and tetracycline and Toremifene: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Bismuth subcitrate, metronidazole, and tetracycline (Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride) label · effective 2026-04-13
Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval.
From the Toremifene (Fareston) label · effective 2024-11-13
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.